Results 121 to 130 of about 33,811 (138)

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

New England Journal of Medicine, 2021
Andre C Kalil, Aneesh K Mehta, Vincent C Marconi   +2 more
exaly  

Remdesivir is a delayed translocation inhibitor of SARS-CoV-2 replication

Molecular Cell, 2021
Jack Bravo, Tyler L Dangerfield, David W Taylor   +2 more
exaly  

Compassionate Use of Remdesivir for Patients with Severe Covid-19

New England Journal of Medicine, 2020
Erika Asperges, Antonella Castagna, Emanuele Nicastri   +2 more
exaly  

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Lancet, The, 2020
Guan-Hua Du, Jianping Zhao, Yang Jin
exaly  

Remdesivir for the Treatment of Covid-19 — Final Report

New England Journal of Medicine, 2020
John H Beigel, Lori E Dodd, Aneesh K Mehta   +2 more
exaly  

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

New England Journal of Medicine, 2020
Jason D Goldman, David Lye, Raffaele Bruno   +2 more
exaly  

Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial

Lancet Respiratory Medicine,the, 2021
Andre C Kalil, Mamta K Jain, Patrick E H Jackson   +2 more
exaly  

Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2

Nature, 2020
Brandi N Williamson, Friederike Feldmann, Benjamin Schwarz   +2 more
exaly  

Remdesivir and COVID-19

Lancet, The, 2020
Jessie K Edwards, Stephen R Cole, Adaora A Adimora   +2 more
exaly   +2 more sources

Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care

Clinical Infectious Diseases, 2021
Katherine K Perez, Alan S Go, Eboni G Price-Haywood   +2 more
exaly